Erik S. Mittra, MD, PhD, explains the literature and rationale behind peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs), including reviewing the NETTER-1 trial that led to its approval. He then discusses the practical aspects and clinical practice of PRRT, how to integrate it in a hospital setting, and future directions for this therapy.Read More
Erik S. Mittra, MD, PhD, CCD
[types usermeta='affiliation' user_is_author='true'][/types]
[types usermeta='location' user_is_author='true'][/types]
Dr. Mittra is an Associate Professor of Radiology, Section Chief of Nuclear Medicine, and Program Director of the Nuclear Medicine Residency, joining OHSU in January 2018. Dr. Mittra received his medical and graduate training through the MSTP (joint MD/PhD) program at Stony Brook University in New York in 2005. His masters degree was in Anatomical Sciences, and his PhD in Biomedical Engineering. His post-graduate training included an internship in Internal Medicine also at Stony Brook University, followed by a residency in Nuclear Medicine and a fellowship in PET/CT imaging both at Stanford University. He stayed on at Stanford as faculty for the subsequent 10 years, most recently as a Clinical Associate Professor of Radiology / Nuclear Medicine, until coming to OHSU. Dr. Mittra is interested in all aspects of Nuclear Medicine imaging, therapy, and research. This includes adult and pediatric general nuclear medicine imaging with gamma camera and SPECT, PET imaging for oncology, cardiac, and neurologic applications, as well as bone densitometry (DXA imaging). Targeted Radioisotope Therapies (TRT) are of particular interest; including various applications in oncology and he is considered a national expert in this area. His research interests are primarily focused on the translation of novel radioisotopes for imaging and therapy to the clinical setting. He is also very involved with the Society of Nuclear Medicine and Molecular Imaging.